<DOC>
	<DOCNO>NCT01249352</DOCNO>
	<brief_summary>The primary objective study assess efficacy nimotuzumab combination chemotherapy radiotherapy treatment locally advanced esophageal cancer , compare conventional treatment radiation chemotherapy . The secondary objective study ass health-related quality life nimotuzumab combination chemotherapy radiotherapy regimen , compare standard chemoradiation regimen treatment inoperable locally advanced esophageal cancer .</brief_summary>
	<brief_title>A Study Chemoradiation Associated With Nimotuzumab Treatment Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description>This phase II , randomize , control , open-label , multicenter , two-arm study . The study conduct Brazil purpose determine activity safety nimotuzumab term overall survival , TTP , clinical endoscopic response rate , resectability rate , toxicity profile , quality life . All participate patient sign consent form undergo study-related procedure . The eligible patient locally advanced esophageal cancer , randomize one two treatment group . Randomization centrally coordinate sponsor perform mean electronic CRF .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Age ≥ 18 year ; 2 . Histological prove SCC esophageal adenocarcinoma ; 3 . T1N1M0 , T2N1M0 , T3N0M0 , T4N0M0 , T3N1M0 , T4N1M0 , qqTqqNM1a stage , accord TNM system42 ; 4 . Life expectation 6 month ; 5 . Inoperable superior , medial , distal third esophageal cancer , include GE junction tumor , define type I II tumor Siewert classification43 ( see Appendix B ) ; 6 . Performance status 0 , 1 , 2 , accord Eastern Cooperative Oncology Group criteria44 ( ECOG ) ( see Appendix C ) ; 7 . Creatinine clearance ≥ 60 ml/min , accord Cockcroft Gault formula45 ( see Appendix D ) ; 8 . Adequate body function , indicate Creatinine clearance ≥ 60 ml/min ; Bilirubin , transaminase , alkaline phosphatase , gammaGT &lt; 1,5 x upper limit normal ; leucocytes ≥ 3000/μl ; granulocyte ≥ 1500/ μl ; hemoglobin ≥ 9 g/dl ; platelet ≥ 80000/ μl ; 9 . Adequate calorie ingestion , investigator 's discretion ; 10 . He/she must sign informed consent form 1 . Previous plan treatment esophageal carcinoma surgery , radiotherapy , chemotherapy , antineoplastic biological therapy ; 2 . Presence active infection ; 3 . Knowledge presence HIV seropositivity ; 4 . Presence severe comorbidities , investigator 's opinion , put patient significantly high risk damage protocol compliance ; 5 . Presence significant neurological psychiatric disease , include dementia seizure , per investigator 's judgment ; 6 . History malignant neoplasm , except adequately treat skin basal carcinoma SCC , cervical carcinoma situ ; 7 . Presence peripheral neuropathy ; 8 . Knowledge presence hypersensitivity allergy drug administer protocol ; 9 . History severe allergic reaction ; 10 . Pregnancy lactation ; 11 . Presence aerodigestive fistula ( trachea and/or bronchia ) ; 12 . Evident presence trachea and/or bronchia infiltration tumor ; 13 . Presence uncontrolled hypercalcaemia ≥ 2.9 mmol/L ( grade &gt; 1 , accord NCICTCAE , version 3.0 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Nimotuzumab</keyword>
	<keyword>EF024</keyword>
	<keyword>EF024-201</keyword>
</DOC>